Compounds for the inhibition of angiogenesis and use thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8501787
APP PUB NO 20070155712A1
SERIAL NO

10593801

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This invention is directed to compounds of structure (I). Particularly this invention is directed to compounds of structure (VIII) wherein the variables are defined as in the description. These compounds are integrin inhibitors and are useful in the treatment of diseases in which an inhibition of angiogenesis is desired.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
TAKEDA PHARMACEUTICAL COMPANY LIMITED1-1 DOSHOMACHI 4-CHOME CHUO-KU OSAKA-SHI OSAKA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Birkner, Sascha Essen, DE 9 51
Hummel, Gerd Berlin, DE 22 178
Knolle, Jochen Berlin, DE 68 504
Osterkamp, Frank Berlin, DE 31 175
Reineke, Ulrich Berlin, DE 34 219
Stragies, Roland Berlin, DE 11 94
Zahn, Grit Berlin, DE 4 73
Zischinsky, Gunther Berlin, DE 13 71

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 6, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00